COMMUNIQUÉS West-GlobeNewswire

Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm
11/09/2025
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented [...]
IVOS Medical Joins NIH’s C3i Program to Accelerate Commercialization of BOSS G4™ Airway Management Technology
11/09/2025
Selection underscores innovation in airway safety and NIH’s support for advancing life-saving medical devices from lab to market IRVINE, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- IVOS Medical, Inc ., a medical device [...]
Prof. Ahmad AbuSalah: KFSHRC’s Sustainable Digital Innovation Ecosystem Features 30+ AI Solutions and 5 New Agents in 2025
11/09/2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Professor Ahmad AbuSalah, Director of the Digital Innovation Hub at King Faisal Specialist Hospital & Research Centre (KFSHRC), said the hospital has developed more than [...]
FOXO TECHNOLOGIES INC. ANNOUNCES ACQUISITION AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.
11/09/2025
WEST PALM BEACH, FL, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (the “Company”), announces that it has signed a stock purchase agreement to acquire Vector Biosource Inc. (“Vector”). Vector is [...]
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
11/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney [...]
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
11/09/2025
SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class [...]
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
11/09/2025
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion [...]
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
11/09/2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will present [...]
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
11/09/2025
New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further Validation of the Systemic [...]
A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry
11/09/2025
The study represents the first successful prospective genetic biomarker-guided drug trial in psychiatry SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC (Denovo), a pioneer in applying precision [...]
First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients
11/09/2025
The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents WAYNE, Pa., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical [...]
RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma
11/09/2025
Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs in oncology HOUSTON and MARSEILLE, France, Sept. 11 [...]
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
11/09/2025
Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the achievement of major clinical milestones SAN MARINO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- [...]
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
11/09/2025
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH) Findings suggest BIOX-101 reduced hematoma volume and slowed perihematomal edema growth [...]
Les données positives de l’essai de phase 2a de Bioxodes montrent le fort potentiel de son candidat médicament innovant BIOX-101 dans l’AVC hémorragique
11/09/2025
Le critère de sécurité a été atteint et des signes encourageants d’efficacité ont été observés lors de l’essai mené auprès de 23 patients touchés par un AVC hémorragique Les résultats suggèrent que BIOX-101 réduit le [...]
US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker
11/09/2025
September 11, 2025 News Release US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker COPENHAGEN, DENMARK and BOSTON, MA, USA, September 11 – BioPorto A/S (“BioPorto” or the “Company [...]
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
11/09/2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody ® and Moditope ® active immunotherapies to treat cancer, today announces a business update [...]
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
11/09/2025
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for [...]
Communiqué de presse : Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire
11/09/2025
Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire Désignation obtenue pour une thérapie génique intravitréenne [...]

Pages